Amanda Smith argues in MIT Technology Review that AI could change embryology work

Amanda Smith argues in MIT Technology Review that AI could change embryology work

Amanda Smith’s article, published October 22, 2025, presents veteran embryologist Klaus Wiemer’s argument that AI could help IVF labs assess embryos and reduce administrative work. Wiemer says CHLOE, an AI tool developed by Fairtility, analyzes embryo development and produces a score to inform embryo selection. Fairtility claims the tool will improve time to pregnancy and live births, but the article says its effectiveness has been tested only retrospectively to date. The proposed change matters to a field the article describes as facing staff shortages and growing workloads. Wiemer says embryologists spend time on non-embryology skills and argues that AI could give them more time to study embryos and improve selection. He also forecasts that clinics will eventually assess embryo development automatically and that reducing transfers of abnormal embryos should not require a biopsy. The article does not establish that these expected changes or claimed patient benefits have occurred. Wiemer’s case for AI is not simply faster selection: he sees it as a way for embryologists to return to scientific work. Whether CHLOE’s retrospective testing translates into improved outcomes in practice remains unknown.

Publication: 02f00bdb-bfe1-38a2-d3db-bc370523ae80

attribution — uncertain: The summary correctly presents the argument as Klaus Wiemer's and the outcome claim as Fairtility's. The title, however, says "Amanda Smith argues" that AI could change embryology work. Smith is the reporting journalist; the belief and forecasts are Wiemer's. Smallest repair: retitle as Wiemer's argument, reported by Amanda Smith in MIT Technology Review.

Klaus Wiemer, a veteran embryologist and IVF lab director, believes artificial intelligence might help by predicting embryo health in real time

summary — uncertain: The summary is mostly faithful, but two issues affect meaning. First, central terms are not explained for a general reader and no definitions are supplied: IVF, biopsy, and especially "tested only retrospectively" (assessed on past data rather than in prospective trials). Second, the summary says clinics will "eventually" assess embryos automatically, but Wiemer's forecast is "in the near future" and covers every embryology laboratory. Smallest repairs: restore "in the near future" and add plain explanations or tooltips for IVF, biopsy and retrospective testing.

In the near future, Wiemer says, reducing the percentage of abnormal embryos that IVF clinics transfer to patients should not require a biopsy

date — pass: October 22, 2025 matches the UTC day of originalPublished (2025-10-22T10:00:00Z). The modifiedAt value precedes publication. Kind is publisher-page, so no archive disclosure is needed. Forecasts are reported as Wiemer's forecasts, not outcomes. The later Deep Dive sidebar items are not used.

support — pass: Each claim matches its quoted source text. Fairtility's outcome claim stays attributed and is qualified by the retrospective-testing caveat. The interpretation claim is labeled as Escape Meridian's and is supported by the excerpt about how embryologists' time would be spent. The question follows from the source's stated testing limitation.

This, the company claims, will improve time to pregnancy and live births. While its effectiveness has been tested only retrospectively to date

media — pass: No media was selected, and no verified media candidates were supplied, so there is no media identity or relevance to check.